TC
Highly rated in
21
conditions
Highly rated in
21
conditions
Check Dr. Toni K. Choueiri's experience treating your condition:
About Dr. Toni K. Choueiri

Toni Choueiri is an Oncologist in Boston, Massachusetts. Choueiri has been practicing medicine for over 23 years and is highly rated in 21 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Orchiectomy, and Prostatectomy. He is licensed to treat patients in Massachusetts. Choueiri is currently accepting new patients.

His clinical research consists of co-authoring 684 peer reviewed articles and participating in 18 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Toni K. Choueiri it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Toni K. Choueiri accepts the following insurance:

  •  Ambetter
  •  Anthem

Call to see if your plan is accepted.
Locations
450 Brookline Ave, Boston, MA 02215
Background & Education
Graduate Institution
Other, 2000
Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Winchester Hospital
Brigham And Womens Hospital
Dana Farber Cancer Institute
Languages Spoken
English
Arabic
Cree
French
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


16 Clinical Trials

A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
A Phase 1/1b Study of SRF388 in Patients With Advanced Solid Tumors
A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Biomarker Study of STA9090 in Castration-Resistant Prostate Cancer (CRPC) With Assessment of Androgen Receptor Pathway Signaling
View 10 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors